What are ADC's

Newsletter sign up

I consent to having ADC Review collect all data required on this form

Check out our Privacy Policy for the full story on how we protect and manage your personal submitted data.

ADC University Our services

ADC Review
is made possible by:

NCT02257567 (Clinical Trial / Polatuzumab Vedotin / DCDS4501A / RG-7596)

Study Title
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (NCT02257567)

Trial Description
This study is a multicenter, open-label study of polatuzumab vedotin (DCDS4501A or RG-7596)  administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib dose-escalation stage and a Phase II stage. The anticipated time on treatment is 18-24 weeks.

This trial is sponsored by Hoffmann-La Roche.

Study Data

  • Condition:
    • Follicular Lymphoma
    • B-Cell Lymphoma
    • Non-Hodgkin’s Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 225
  • Start: October 2014
  • Estimated Completion: June 2019
  • Last verified: November 2017

Drug Description

Study Schematic

Click here to Return to Drug map

Last Editorial review: December 19, 2017
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

ADCs – Look Forward to a Potent Future

27 September, 2018

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In this second article, Penelope Drake and David Rabuka, of...

How to Contribute

Skip to toolbar